Contribute Try STAT+ Today

Amid growing concern over access to Covid-19 medical products, Moderna (MRNA) has decided not to enforce its patent rights related to its experimental vaccine and will also license its intellectual property to any Covid-19 vaccines to others after the pandemic has ended.

The decision means other companies or governments should not have concerns that the biotech would seek to prevent other Covid-19 vaccines from being developed based on its technology. “We feel a special obligation under the current circumstances to use our resources to bring this pandemic to an end as quickly as possible,” the company said in a brief statement (here are the patents).

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.